Genpharm
Dubai-based pharmaceutical market access company founded in 2012 that provides fast-track commercialization, regulatory, and distribution services for global biotech and pharma companies launching rare disease and specialty therapies across the MENAT region, operating in 12+ countries with 80+ employees.
- Company typePrivate
- Founded2012
- HeadquartersDubai, United Arab Emirates
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Genpharm does
Genpharm is a Dubai-headquartered pharmaceutical market access company founded in 2012 by Karim Smaira and Kamel Ghammachi to address gaps in rare disease care across the Middle East, North Africa, and Turkey (MENAT) region. The company operates as the exclusive regional commercial partner for global pharmaceutical and biotechnology firms seeking to introduce rare disease and specialty therapies into the MENAT region, with a portfolio covering neuromuscular, lysosomal storage, ophthalmic, metabolic, and gene therapy products. Named partnerships include exclusive distribution rights for Vyvgart (argenx, generalized Myasthenia Gravis), Galafold (Amicus Therapeutics, Fabry disease), Mepsevii (Ultragenyx, MPS VII), Libmeldy (Orchard Therapeutics, metachromatic leukodystrophy gene therapy), and intravitreal pegcetacoplan (Apellis, geographic atrophy).
Genpharm's business model is built on multi-year exclusive commercialization and distribution agreements under which it captures product sales, distribution margins, and commercialization fees from its pharma partners, complemented by professional services revenue from advisory work on pricing, reimbursement, and regulatory strategy. The company maintains operational offices in the UAE (headquarters), Saudi Arabia (scientific office in Riyadh), Turkey (liaison in Ankara), Lebanon (Beirut), and Kuwait (Salmiya), employing more than 80 associates across cross-functional teams that include Medical Science Liaisons, regulatory affairs, medical affairs, and field sales. In 2019, Genpharm became the first company to successfully launch gene therapy in the MENAT region via its Libmeldy partnership.
Following the January 2024 acquisition of a majority stake by Abdul Latif Jameel Health (part of the diversified Abdul Latif Jameel group), Genpharm has begun extending its market access platform beyond rare disease pharmaceuticals into medical technology, evidenced by 2026 MOUs with Nanoflex Robotics (endovascular telerobotics) and Nanovision (phased array CT imaging). The core technology stack is conventional pharmaceutical distribution and market access infrastructure rather than proprietary software or AI platforms, with the company's defensibility resting on regulatory expertise, KOL relationships, and exclusive distribution rights rather than technology differentiation.
Genpharm firmographics
Firmographics- Name
- Genpharm
- Legal name
- Genpharm Services
- Website
- https://genpharmservices.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Dubai-based pharmaceutical market access company founded in 2012 that provides fast-track commercialization, regulatory, and distribution services for global biotech and pharma companies launching rare disease and specialty therapies across the MENAT region, operating in 12+ countries with 80+ employees.
- Ownership category
- akta.pro rank
Genpharm industry classification
Industry- Product category
- Pharmaceutical Market Access Services
- NAICS
- Drugs and Druggists' Sundries Merchant Wholesalers (424210), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Specialty Pharmacy & Biologics Distribution (CRAOAHAD)
- akta.pro secondary industries
- Specialty Care Pharmaceuticals (HLAIAAAB), Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA), Rare Endocrine & Growth Disorder Therapies (HLAIAIAJ)
Keywords
Where Genpharm is headquartered
LocationHeadquarters
- HQ city
- Dubai
- HQ country
- United Arab Emirates
- HQ region
- Middle East
Offices5 records
Markets served
Genpharm business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Supply Chain, Technology or R&D, Others
Revenue model
- Commercialization and Distribution Agreements: Genpharm acts as the exclusive regional commercial partner for global pharmaceutical and biotech companies, commercializing and distributing rare disease and specialty drugs across the MENAT region. Revenue is generated through product sales, distribution margins, and commercialization fees under exclusive partnership agreements.
- Market Access Services: Genpharm provides market access advisory services including strategic planning, go-to-market strategies, pricing and reimbursement solutions, regulatory affairs, and medical affairs support to pharmaceutical partners entering the MENAT region.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
Genpharm product offering
Product offeringCore offering
Genpharm is the exclusive regional commercial partner for global pharmaceutical and biotech companies, providing market access for rare disease and specialty therapies across the Middle East, North Africa, and Turkey (MENAT) region. The company commercializes and distributes a portfolio of approved rare disease drugs (including gene therapies) and provides end-to-end services covering regulatory affairs, pricing and reimbursement, medical affairs, pharmacovigilance, and field sales to healthcare providers, KOLs, and patient associations.
Product overview
Genpharm is a specialty healthcare company providing market access services for rare diseases and specialty pharmaceuticals across the Middle East, North Africa, and Turkey (MENAT) region. The company's core offerings include a portfolio of approved therapies for rare diseases (VYVGART for Myasthenia Gravis, Galafold for Fabry Disease, Mepsevii for MPS VII, Libmeldy gene therapy for MLD, pegcetacoplan for Geographic Atrophy) and strategic partnerships for advanced medical technologies (Nanoflex endovascular robotics, Nanovision Phased Array CT imaging). Genpharm operates as the exclusive regional commercial partner for global pharmaceutical and biotech companies, providing regulatory affairs, market access, medical affairs, pharmacovigilance, and supply chain management services. The company was established in 2012 and operates across more than 12 countries, having pioneered the introduction of gene therapy to the MENAT region in 2019.
Differentiator
Problem solved
Functional benefit
Products and services
- VYVGART (efgartigimod alfa-fcab) FDA-approved antibody-based medicine (neonatal Fc receptor blocker) for treatment of generalized Myasthenia Gravis (gMG) in adult patients who are anti-AChR antibody positive; commercialized in the Gulf Region through an exclusive agreement with argenx SE.
- Galafold (migalastat) First and only oral precision medicine for Fabry disease, approved in over 40 countries; commercialized in the GCC by Genpharm for patients aged 12 years and older with amenable mutations, under an exclusive distribution agreement with Amicus Therapeutics.
- Mepsevii (vestronidase alfa-vjbk) FDA and EMA-approved enzyme replacement therapy for Mucopolysaccharidosis VII (MPS VII, Sly Syndrome); the first and only approved treatment for this rare metabolic disorder, commercialized by Genpharm in the GCC under an exclusive agreement with Ultragenyx.
- Libmeldy (atidarsagene autotemcel) Ex vivo autologous gene therapy for Metachromatic Leukodystrophy (MLD); Genpharm facilitates access to treatment at European-based qualified treatment centres for eligible Middle East patients, under an agreement with Orchard Therapeutics.
- Intravitreal pegcetacoplan FDA-approved intravitreal therapy for Geographic Atrophy (GA), an advanced stage of age-related macular degeneration; commercialized in UAE, KSA, Oman, Qatar, Kuwait, and Bahrain under an exclusive agreement with Apellis Pharmaceuticals.
- CompoundEye 24 Phased Array CT System World's first Phased Array CT imaging system using electronically controlled multiple X-ray sources (no mechanical gantry rotation), developed by Nanovision; intended for introduction to the MENA region under a strategic partnership with Genpharm.
- Nanoflex Endovascular Robotics Platform Magnetically controlled telerobotic system for endovascular interventions, developed by Nanoflex Robotics (ETH Zurich spin-out); to be introduced into Gulf and Levant markets under a strategic MOU with Genpharm covering regulatory, clinical, and commercial pathways.
Quantifiable outcome
- Successfully launched gene therapy in MENAT region in 2019, making Genpharm the first company to do so.
- +1 more outcomes
Companies that use Genpharm
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles2 records
Genpharm technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Genpharm partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered strategic exploration and core.
- Nanoflex Roboticsstrategic explorationNanoflex Robotics (Swiss developer of magnetically controlled telerobotic systems for endovascular interventions) signed an MOU with Genpharm to explore strategic collaboration for endovascular robotics across the Gulf and Levant. The collaboration aims to expand access to advanced, minimally invasive endovascular treatments, promote awareness for robotically driven systems, facilitate clinical engagement, evaluate regulatory pathways, and prepare commercial roll-out.
- Nanovisionstrategic explorationNanovision (medical imaging innovator) partnered with Genpharm to introduce Phased Array CT technology to the MENA region. The partnership combines Nanovision's next-generation imaging technology with Genpharm's regional market access expertise and clinical network to support introduction of the new CT imaging architecture. The MoU covers regulatory strategy, market entry, and clinical engagement.
- Apellis PharmaceuticalscoreGenpharm entered an exclusive agreement with Apellis Pharmaceuticals to market and sell intravitreal pegcetacoplan upon regulatory approval in UAE, Saudi Arabia, Oman, Qatar, Kuwait, and Bahrain. Pegcetacoplan received FDA approval for geographic atrophy (GA), an advanced stage of age-related macular degeneration and a leading cause of blindness.
- argenxcoreGenpharm signed an exclusive commercial and distribution agreement with argenx SE to commercialize VYVGART (efgartigimod alfa-fcab) for generalized Myasthenia Gravis (gMG) in the Gulf Region. Vyvgart is FDA-approved for adult patients who are anti-AChR antibody positive.
- Amicus TherapeuticscoreGenpharm signed an exclusive distribution agreement with Amicus Therapeutics to commercialize Migalastat (marketed as Galafold capsules 123mg) for the treatment of amenable Fabry disease patients aged 12 and older in the Gulf Cooperation Council. Galafold is the first and only oral precision medicine for Fabry Disease, approved in over 40 countries.
- Orchard TherapeuticscoreGenpharm entered into an agreement with Orchard Therapeutics to facilitate access to Libmeldy for eligible patients living with Metachromatic Leukodystrophy (MLD) in European-based qualified treatment centres for eligible patients from the Middle East. Libmeldy is an ex vivo autologous gene therapy.
- UltragenyxcoreGenpharm entered into an agreement with Ultragenyx for the commercialization and distribution of Mepsevii (vestronidase alfa-vjbk) in the GCC region. Mepsevii is FDA and EMA approved for the treatment of pediatric and adult patients with Mucopolysaccharidosis VII (MPS VII, Sly Syndrome) and is the first and only therapy for MPS VII.
Scale indicators6 records
Recent moves8 records
Expansion highlights5 records
Genpharm competitors and assessment
Company assessmentDirect peers
- NewBridge Pharmaceuticals: Dubai-headquartered specialty pharma company that partners with global biotechs to commercialize therapies in the MENAT region — the closest direct comparable to Genpharm in business model, geography, and therapeutic focus.
- Medison Pharma: Israel-headquartered specialty pharma company commercializing innovative therapies across international markets, including MENA. Comparable in partnering with global biotechs for regional specialty/rare-disease access.
- Biologix: MENA-focused biopharmaceutical distribution and commercialization partner that brings innovative therapies to regional markets, with overlapping business model and customer set in specialty distribution.
Regional players
- Algorithm SAL: Lebanese pharmaceutical marketing and distribution company with regional MENAT presence, providing commercialization services to global pharma — comparable in go-to-market motion though more established in Lebanon and Levant.
- Pharmax Pharmaceuticals: UAE-based pharmaceutical marketing and distribution company focused on specialty and innovative therapies in the Gulf — comparable in MENAT distribution role and specialty focus.
Broad incumbents
- Tabuk Pharmaceuticals: Saudi-headquartered pharmaceutical company manufacturing and marketing branded generics and specialty products across MENAT. Overlaps in regional distribution footprint and therapeutic breadth but is manufacturing-led.
- SPIMACO: Leading Saudi Arabian pharmaceutical manufacturer and distributor with MENAT commercial reach. Comparable in regional distribution scale but focused on generic and branded manufacturing rather than rare-disease specialty.
- Hikma Pharmaceuticals: A leading MENA-headquartered pharmaceutical company with branded generics, injectables, and specialty businesses across the region. Overlaps with Genpharm in MENAT specialty distribution but operates at much larger scale across broader therapeutic areas.
- Julphar (Gulf Pharmaceutical Industries): One of the largest pharmaceutical manufacturers in the MENA region (UAE-based), with regional distribution infrastructure. Comparable in MENAT presence but vertically integrated in manufacturing rather than partnership-driven commercialization.
- AstraZeneca MENAT: Global biopharma with significant rare-disease and specialty operations in MENAT. Comparable in therapeutic focus areas (rare disease, oncology) but operates direct regional infrastructure rather than partnership-based commercialization.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Genpharm social profiles
Digital presenceGenpharm financial estimates
Financial estimateRevenue estimate
Valuation estimate
Genpharm leadership team
Management profileNumber of profiles
Profiles4 records
Genpharm funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Genpharm M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Genpharm
What does Genpharm do?
Genpharm is the exclusive regional commercial partner for global pharmaceutical and biotech companies, providing market access for rare disease and specialty therapies across the Middle East, North Africa, and Turkey (MENAT) region. The company commercializes and distributes a portfolio of approved rare disease drugs (including gene therapies) and provides end-to-end services covering regulatory affairs, pricing and reimbursement, medical affairs, pharmacovigilance, and field sales to healthcare providers, KOLs, and patient associations.
Is Genpharm a public or private company?
Genpharm is a private company. It is classified as corporate owned and is currently operating.
When was Genpharm founded?
Genpharm was founded in 2012. It employs 11 to 50 people.
Where is Genpharm based?
Genpharm is headquartered in Dubai, United Arab Emirates, in the Middle East region.
How does Genpharm make money?
Two revenue lines are on record. Commercialization and Distribution Agreements are the primary driver. The others are market Access Services.
Who are Genpharm's main competitors?
Direct peers on record are NewBridge Pharmaceuticals, Medison Pharma and Biologix. Regional players are Algorithm SAL and Pharmax Pharmaceuticals. Broad incumbents are Tabuk Pharmaceuticals, SPIMACO, Hikma Pharmaceuticals, Julphar (Gulf Pharmaceutical Industries) and AstraZeneca MENAT.
Does Genpharm have an API?
No public API is recorded for Genpharm.
What industry is Genpharm in?
Genpharm's product category is Pharmaceutical Market Access Services. Its primary akta.pro industry code is CRAOAHAD, Specialty Pharmacy & Biologics Distribution, with a secondary code of HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 424210 and its SIC code is 5122.